Skip to main content
. 2016 Jul 8;6(7):e442. doi: 10.1038/bcj.2016.51

Figure 5.

Figure 5

Impacts of KIT-AL and TET2 mutations and HSCT at CR1. (a) Kaplan–Meier analyses showing that patients who were negative for both KIT-AL and TET2 mutations had superior LFS and OS compared with those who were positive for either or both of these mutations. (b) Kaplan–Meier analyses showing that patients receiving HSCT at CR1 were associated with superior LFS but not OS.